Proportion of heart failure patients age 18 and older with LVSD for whom beta-blocker therapy (i.e., bisoprolol, carvedilol, or sustained-release metoprolol succinate) is prescribed at discharge. For purposes of this measure, LVSD is defined as chart documentation of a left ventricular ejection fraction (LVEF) less than 40% or a narrative description of left ventricular systolic (LVS) function consistent with moderate or severe systolic dysfunction.
-
-
1.5 Measure Type1.7 Electronic Clinical Quality Measure (eCQM)1.9 Care Setting1.20 Testing Data Sources
-
1.14 Numerator
Patients who are prescribed bisoprolol, carvedilol, or sustained-release metoprolol succinate for LVSD at hospital discharge.
-
1.15 Denominator
Heart failure patients with current or prior documentation of left ventricular ejection fraction (LVSD) < 40%.
-
Exclusions
Excluded Populations:
• Patients who had a left ventricular assistive device (LVAD) or heart transplant procedure during hospital stay (ICD-10-PCS procedure code for LVAD and heart transplant as defined in Appendix A, Table 2.2)
• Patients less than 18 years of age
• Patients who have a Length of Stay greater than 120 days
• Patients with Comfort Measures Only documented
• Patients enrolled in a Clinical Trial
• Patients discharged to another hospital
• Patients who left against medical advice
• Patients who expired
• Patients discharged to home for hospice care
• Patients discharged to a healthcare facility for hospice care
• Patients with a documented Reason for No Bisoprolol, Carvedilol, or Sustained-Release Metoprolol Succinate Prescribed for LVSD at Discharge
-
Most Recent Endorsement ActivityMeasure Retired and Endorsement Removed Cardiovascular Fall Cycle 2018Initial EndorsementLast UpdatedRemoval Date
-
StewardThe Joint CommissionSteward Organization POC EmailSteward Organization Copyright
This measure resides in the public domain and is not copyrighted
-
-
-
Risk Adjustment
-